Orphan drugs will make up a fifth of the forecasted $1.6 trillion in worldwide prescription drug sales by 2030, according to Evaluate’s 2025 Orphan Drug Report.  The 2025 report, based on Evaluate Pharma forecasts, projects that the segment will continue to outpace the wider pharmaceutical market for the next few years but its growth advantage […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!